How to cite item

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study

   
@article{TLCR4219,
	author = {Kazushi Yoshida and Yasuhide Yamada},
	title = {Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study},
	journal = {Translational Lung Cancer Research},
	volume = {4},
	number = {3},
	year = {2015},
	keywords = {},
	abstract = {The JO25567 study was a randomized phase II study to investigate the efficacy of the combination therapy consisted with erlotinib and bevacizumab for non-squamous nonsmall- cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutation (1). The study showed that the progression-free survival (PFS) of the combination therapy group was longer than that of the erlotinib monotherapy group. The median PFS were 16.0 months (95% CI, 13.9-18.1) vs. 9.7 months (95% CI, 5.7-11.1) respectively. The over-all survival (OS) data are immature, but this study suggested a remarkable efficacy of this combination chemotherapy.},
	issn = {2226-4477},	url = {https://tlcr.amegroups.org/article/view/4219}
}